Markets:

Overview

News

Currencies

International

Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

56.90 -0.79 (-1.37%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Nektar Therapeutics Announces Positive Data From Eczema Drug In Mid-stage Trial: Stock More Than Doubles But Retail Sees It Rising Further ↗

June 24, 2025

Nektar Therapeutics said its mid-stage trial showed that patients who received Rezpegaldesleukin demonstrated improvement in eczema area and severity score compared to placebo at week 16.

Via Stocktwits

Topics Economy Government

Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1 ↗

June 24, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

June 24, 2025

Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Which stocks are gapping on Tuesday? ↗

June 24, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Nektar Therapeutics's Earnings: A Preview ↗

May 07, 2025

Via Benzinga

Nasdaq Surges 1%; TD Synnex Posts Upbeat Earnings ↗

June 24, 2025

Via Benzinga

Nektar Therapeutics Shares Double On Promising Eczema Drug Data ↗

June 24, 2025

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a consistent safety profile.

Via Benzinga

Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam ↗

June 24, 2025

The company's experimental eczema drug met all the primary and secondary goals in a midstage study.

Via Investor's Business Daily

Tuesday's pre-market session: top gainers and losers ↗

June 24, 2025

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Sweet Nektar? ↗

April 22, 2024

NKTR has had a terrible time of it for years, but maybe it’s finally ready to turn around.

Via Talk Markets

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 24, 2025

Via Benzinga

Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket ↗

June 24, 2025

Via Benzinga

US Stocks Likely To Open Higher After Trump Announces Iran-Israel Ceasefire: FedEx, TD Synnex In Focus Ahead Of Earnings ↗

June 24, 2025

U.S. futures were trading higher on Tuesday after a positive day of trade on Monday. Futures of major benchmark indices were trading higher.

Via Benzinga

Topics Government

Nektar Therapeutics Stock Rallies Sharply After-Hours With Major Skin Drug Results Just Hours Away ↗

June 23, 2025

Rezpegaldesleukin is being studied not only in atopic dermatitis but also in alopecia areata, with topline data from the second trial expected in December.

Via Stocktwits

12 Health Care Stocks Moving In Monday's After-Market Session ↗

June 23, 2025

Via Benzinga

Top movers in Monday's after hours session ↗

June 23, 2025

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Assessing Nektar Therapeutics: Insights From 5 Financial Analysts ↗

April 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 14, 2025

Via Benzinga

Assessing Nektar Therapeutics: Insights From 4 Financial Analysts ↗

March 13, 2025

Via Benzinga

Earnings Scheduled For March 12, 2025 ↗

March 12, 2025

Via Benzinga

Top movers in Friday's after hours session ↗

February 21, 2025

As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 10, 2025

Via Benzinga

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

January 08, 2025

Via Benzinga

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential ↗

November 04, 2024

Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment.

Via Benzinga

10 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 04, 2024

Via Benzinga

NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

NKTR stock results show that Nektar Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

NKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

NKTR stock results show that Nektar Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 07, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 30, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Nektar Therapeutics - Common Stock (NQ:NKTR)

All News about Nektar Therapeutics - Common Stock

Starting at $3.75/week.

Subscribe Today